Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men

M. Acharya · A. Bernard · M. Gonzalez · J. Jiao · R. De Vries · N. Tran

Received: 20 February 2012 / Accepted: 26 March 2012 / Published online: 18 April 2012 © The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract

Purpose To evaluate pharmacokinetics, safety, and tolerability of abiraterone acetate (AA) in healthy men.

Methods Two phase I studies (dose-escalation study and dose-proportionality study) were conducted in healthy men aged 18–55 years. All subjects received 4 consecutive single doses of AA (250, 500, 750 and 1,000 mg). The dose-escalation study subjects (N = 33) received AA doses in a sequential manner, starting with the lowest dose. The dose-proportionality study subjects (N = 32) were randomly allocated (1:1:1:1) to receive each of the 4 doses in a four-way crossover design.

Results A dose-related increase in abiraterone exposure was observed in both studies. Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration–time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study. In the dose-proportionality study, abiraterone exposure was dose proportional between 1,000 and 750 mg doses; however, the exposure was slightly greater than dose proportional when exposures at 500 and 250 mg doses were compared with the exposure at 1,000 mg. Single doses of AA were well tolerated in healthy men, and safety profile was consistent with its known toxicities in CRPC patients.

Conclusion Systemic exposure to abiraterone increased with increasing doses of AA (250–1,000 mg) in healthy men; AA was well tolerated in this population.

Keywords Abiraterone acetate · Dose-proportionality · Pharmacodynamics · Pharmacokinetics · Prostate cancer

Introduction

Prostate cancer is the second leading cause of cancer deaths, accounting for 9 % of all cancer-related death in men [1]. Androgen deprivation therapy (ADT) is a standard treatment for advanced, adjuvant, and non-adjuvant stages of the disease and involves surgical (orchietomy) or medical (luteinizing hormone (LH)-releasing hormone agonists, or antiandrogens) intervention [2, 3]. Although ADT induces a remission in 80–90 % of patients with advanced disease [4], majority of patients eventually develop castration-resistant prostate cancer (CRPC), an androgen-independent phenotype and the lethal form of the disease, in which <20 % of patients survive beyond 3 years [5]. New therapeutic strategies, which can offer better protection against CRPC, would be useful.

The enzyme 17α-hydroxylase/C17, 20-lyase (CYP17) catalyzes critical reactions in the synthesis of androgens [6]. Ketoconazole, the non-selective inhibitor of CYP17 enzyme, presents modest antitumor activity and is associated with an increase in androgenic steroids at disease progression, indicating incomplete target blockade [7]. Abiraterone is a selective and irreversible inhibitor of CYP17 enzyme and is 10–30-fold more potent than ketoconazole [8]. A prodrug of abiraterone, abiraterone acetate...
(AA), was developed to overcome its poor bioavailability. Abiraterone acetate (ZYTIGA®) in combination with prednisone is approved in the United States [9], Canada [10], and Europe [11] for the treatment of male subjects with metastatic castration-resistant prostate cancer, who have received prior chemotherapy containing docetaxel.

The safety and tolerability of AA was demonstrated in two dose-escalation studies in CRPC patients, and no dose-limiting toxicity was identified at doses up to 2,000 mg [5, 12]. In this report, we present the results from two phase I studies (dose-escalation study and dose-proportionality study) in healthy men, which evaluated pharmacokinetics (PK) and safety of AA at doses of 250, 500, 750, and 1,000 mg. Additionally, in the dose-proportionality study, pharmacodynamic evaluation was carried out to assess the effect of abiraterone on levels of testosterone and LH.

Methods

Study population

Healthy men between 18 and 55 years of age (inclusive), with body mass index within 18 to 32 kg/m² (inclusive), were enrolled in both studies. Subjects were in good general health as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory measurements; they had negative test results for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, selected drugs of abuse, and breathalyzer alcohol and had not consumed nicotine or nicotine-containing products in 1 year before enrollment. All subjects used an acceptable method of contraception from day-1 until 30 days following the completion of studies.

Exclusion criteria were a significant history or clinical manifestation of any significant diseases or disorders, history of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of drugs, abnormal ECG, or hypersensitivity reaction to the study drug or related compounds.

Subjects agreed to refrain from consuming grapefruit- or caffeine-containing products (for 72 h before day-1 until after collection of 96-h PK sample for the dose-escalation study and throughout the study for the dose-proportionality study) and alcohol-containing products (for 24 h before day-1 until the end of study in both studies). Additionally, they refrained from strenuous exercise from 48-h before day-1 and during the period of confinement at the clinical research unit (CRU) for the dose-escalation study and throughout the study for the dose-proportionality study.

Concomitant medications were not allowed during both studies with the exception of acetaminophen and non-steroidal anti-inflammatory drugs, which were allowed after the 96-h PK sample collection.

Both studies were conducted in accordance with the ethical principles that have their origin in the declaration of Helsinki and that are consistent with good clinical practices, applicable regulatory requirements, and in compliance with the respective protocols. The study protocols were reviewed and approved by an independent institutional review board (Florida, USA). All subjects provided written informed consent before entering the studies.

Study designs

The dose-escalation study, conducted from December 17, 2008, to April 02, 2009, was an open-label study with a 14-day screening phase and up to 88-day treatment phase (approximately 22 days for each of the 4 single-dose cohorts). The dose-proportionality study, conducted from March 30, 2010, to May 1, 2010, was an open-label, randomized, four-way crossover study, with a 21-day screening phase and a 28-day treatment phase (consisting of 4 consecutive, 7-day treatment periods). Both studies were conducted at Covance Clinical Research Unit Inc., Texas, United States of America.

Abiraterone acetate (manufactured by Pharmaceutical International, Inc., Maryland) was provided as 250-mg tablets. In both studies, AA was administered at doses of 250, 500, 750, and 1,000 mg/day. In the dose-escalation study, these doses were administered to subjects in 4 dose cohorts in a sequential manner, starting with the lowest dose (250 mg/day). Dose administration for subsequent cohorts was started at least 15 days after dosing of the preceding cohort and after the safety data were reviewed and assessed as not having any safety concerns such as clinically significant adverse event indicative of drug intolerance; clinically significant finding for physical examination, 12-lead ECG, or vital signs; or clinically significant change in laboratory parameter. Due to an error in PK sample processing at the CRU for the Cohort 2 dose level (500 mg), another 500-mg dose level cohort was added and designated as Cohort 2a. The bio-analytical data for Cohort 2 was not evaluated.

In the dose-proportionality study, 32 eligible subjects were randomized (1:1:1:1) to receive 1 of the 4 treatment sequences: ADBC, BACD, CBDA, DCAB. Each treatment sequence included 4 doses of AA: 250 mg/day (treatment A), 500 mg/day (treatment B), 750 mg/day (treatment C), and 1,000 mg/day (treatment D). For each subject, dose administration for subsequent treatment in the treatment sequence was started 7 days after dosing of the preceding treatment.

All subjects fasted for at least 10 h before and 4 h after AA administration in both studies. Subjects were confined to CRU one day before every administration of AA and...
of each dose cohort in dose-escalation study and on days 3, 4, and 7 of each treatment period in the dose-proportionality study, for study procedures.

Pharmacokinetic evaluation

During both studies, blood samples were collected for the measurement of AA and abiraterone concentrations in plasma; samples were collected from the peripheral vein (via an indwelling catheter or direct venipuncture), within 0.5 h before the dose (predose sample) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 h postdose. Additionally, in the dose-proportionality study, blood samples for evaluation of serum testosterone and LH were also collected on day 1 (predose and 2 and 12 h postdose), 2, 3, 4, and 5 of each cohort and at the end of study or early withdrawal visit.

Bioanalytical method

Concentrations of abiraterone and AA were determined using a validated bioanalytical method employing ultra performance liquid chromatography with tandem mass spectrometric detection. The calibration range for abiraterone was 0.2–200 ng/mL for the dose-escalation study and 0.2–500 ng/mL for the dose-proportionality study. The calibration range for AA was 0.2–50 ng/mL for both studies.

Data analysis

For the dose-escalation study, non-compartmental analysis was performed using WinNonlin (Pharsight Corporation, Version 5.2). SAS version 9.1 was used for all statistical calculations, tables, and plots. For the dose-proportionality study, non-compartmental analysis was performed using WinNonlin (Version 4.0.1b). SAS version 9.1 was used for confidence interval testing. Tables and plots were created using PKAA 1.0, which utilized Microsoft Excel 2000.

Pharmacokinetic parameters

Pharmacokinetic parameters calculated from plasma concentration–time data were maximum plasma concentration (Cmax), time to reach Cmax (tmax), and area under the plasma concentration–time curve (AUC) from 0 to the last measurable plasma concentration as calculated by the linear trapezoidal rule (AUC0–last); AUC extrapolated to infinity (AUC0–∞), calculated as: AUC0–∞ = AUC0–last + C∞/λz, where C1 was the last measurable plasma concentration and λz was the apparent terminal phase rate constant calculated as the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase; and apparent plasma terminal elimination half-life t1/2 (whenever possible), where t1/2 = (ln2)/λz.

Safety evaluations

Safety assessments included monitoring treatment-emergent adverse events (TEAEs), clinical laboratory tests, ECG, vital sign measurements, and physical examinations. The severity of adverse events (AEs) was assessed using the National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE, version 3.0, grades 1, 2, 3, and 4) [13]. In addition, total testosterone and LH levels on days 1, 3, 5, 8, and 15 of each cohort in the dose-escalation study and on day 1 (predose and 2 and 12 h postdose) and day 2 through day 5 in each treatment period in the dose-proportionality study were evaluated. These evaluations were repeated approximately 7 days after the end of study, for subjects whose serum testosterone levels were not within the normal limits or below the baseline value at the end of study. In the dose-proportionality study, testosterone levels were monitored every 7 days until the levels returned to baseline or to within normal limits.

Statistical analysis

In both studies, PK analysis sets included all subjects who received the study drug and had at least 1 valid PK parameter estimate, and the safety analysis sets included all subjects who received at least one dose of study drug.

Plasma concentration data of abiraterone and all estimated PK parameters were summarized descriptively for both studies. For the dose-proportionality study, least squares means (LSM) and intra-subject variance were estimated using a mixed-effect model, which included treatment, period, and treatment sequence as fixed effects and participant as a random effect.

Sample size determination

Approximately 32 subjects were to be enrolled in the dose-escalation study based upon samples sizes used in previous PK studies of similar nature. For the dose-proportionality study, the sample size of 24 subjects (using an estimated intra-subject coefficient of variation of 21 % for AUC0–last and AUC0–∞) was sufficient for the point estimates of the ratio of AUC0–last and AUC0–∞ to fall within 90–111 % of the true value with 90 % confidence. This sample size was also sufficient for the point estimate of the ratio of Cmax to fall within 86–116 % of the true value with 90 % confidence using an estimated intra-participant coefficient of variation of 31 % for Cmax. Thirty-two subjects were
randomized in the dose-proportionality study in order to obtain at least 24 subjects who completed the study.

Results

Subject disposition and baseline characteristics

In the dose-escalation study, 40 men were screened, 33 were enrolled, 8 were assigned to each dose cohort, and all completed the study. Dose cohort 2a (500 mg/day, repetition of cohort 2) included 7 subjects from cohort 2 and one new participant. In the dose-proportionality study, 32 men were enrolled, 27 completed the study, 3 discontinued due to non-compliance, and 2 were lost to follow-up. Baseline and demographic characteristics of subjects from both studies are presented in Table 1.

Pharmacokinetics of abiraterone acetate

The PK analysis was not performed for AA as the majority of plasma concentrations for AA were below the limit of quantification in both studies.

Pharmacokinetics of abiraterone

Following the administration of AA, the mean abiraterone plasma concentrations increased relatively rapidly to peak and declined in a biphasic manner, in both studies. The mean concentration–time profiles of abiraterone obtained in two studies are presented in Fig. 1.

Table 1  Demographic and baseline characteristics of subjects (safety analysis set)

|                          | Dose-escalation study (N = 33) | Dose-proportionality study (N = 32) |
|--------------------------|---------------------------------|-------------------------------------|
| Age (years), mean (range)| 37 (22–54)                      | 35.5 (22–54)                        |
| Ethnicity, n (%)         |                                 |                                     |
| Hispanic/latino          | 11 (33.3)                       | 12 (37.5)                           |
| Non-Hispanic/latino      | 22 (66.7)                       | 20 (62.5)                           |
| Race, n (%)              |                                 |                                     |
| White                    | 19 (57.6)                       | 22 (68.8)                           |
| Black or African American| 13 (39.4)                       | 7 (21.9)                            |
| Asian                    | 1 (3)                           | 1 (3.1)                             |
| American Indian/Alaska Native | 0 (0)                          | 1 (3.1)                             |
| Other                    | 0                               | 1 (3.1)                             |
| BMI (kg/m²), mean (range)| 26.0 (19.2–32.0)                | 26.6 (21–30)                        |

BMI  body mass index

Dose-escalation study

The abiraterone plasma concentrations and exposures generally increased with increase in dose (Table 2). The inter-subject variability [coefficient of variation (CV %)] for \( C_{\text{max}} \), AUC\(_{0-\infty}\), and AUC\(_{0-t}\) ranged from 38.8 to 53.6 % for the 250 mg/day cohort, 46.9–60.0 % for the 500 mg/day cohort, 57.0–58.4 % for the 750 mg/day cohort, and 32.7–40.8 % for the 1,000 mg/day cohort. The mean \( t_{1/2} \) ranged from 11.1 to 14.7 h in Cohorts 1 through 4. Abiraterone mean \( t_{1/2} \) and median \( t_{\text{max}} \) values appeared to be independent of dose.

Dose-proportionality study

Median \( t_{\text{max}} \) occurred at 2 h after administration and mean \( t_{1/2} \) ranged from 14.4 to 16.5 h. The mean exposures increased with increase in dose (Table 2). Inter-subject
variability (CV %) was relatively high and ranged from 49.8 to 63.4 % for Cmax and 42.0–55.8 % for the AUCs. Dose-normalized geometric mean ratios for Cmax and AUC showed that abiraterone exposure decreased dose-proportionally at 750 mg (90 % confidence interval within 80–125 %) but not at 500 or 250 mg (Table 3).

Safety

In the dose-escalation study, overall, 23 TEAEs were reported by 9 (27.3 %) subjects: 2 each from 250, 500, and 1,000 mg/day cohorts and 3 from 750 mg/day cohort; all of the TEAEs were mild in nature. Overall, the most common

Table 2 Pharmacokinetic parameters of abiraterone in dose-escalation study and dose-proportionality study (pharmacokinetic analysis set)

| Parameter | Dose cohort 1 (250 mg/day) | Dose cohort 2 (500 mg/day) | Dose cohort 3 (750 mg/day) | Dose cohort 4 (1,000 mg/day) |
|-----------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Cmax (ng/mL), mean (SD) | 25.9 (10.0) | 76.6 (35.9) | 57.4 (32.7) | 112 (36.7) |
| tmax (h), median (min, max) | 1.75 (1.0, 4.0) | 2.02 (1.0, 3.0) | 1.75 (1.0, 3.0) | 1.75 (1.0, 3.0) |
| AUC0-last (ng h/mL), mean (SD) | 155 (83.3) | 428 (257) | 309 (180) | 610 (249) |
| AUC0-infinity (ng h/mL), mean (SD) | 162 (84.7) | 440 (254) | 317 (183) | 617 (249) |
| t1/2 (h), mean (SD) | 11.1 (2.97) | 14.6 (4.70) | 14.7 (3.96) | 12.7 (1.91) |

Cmax = the maximum plasma concentration; tmax = time to reach Cmax; AUC0-last = area under the plasma concentration–time curve (AUC) from 0 to the last measurable plasma concentration; AUC0-infinity = AUC extrapolated to infinity

Table 3 Dose-normalized pharmacokinetic parameters of abiraterone estimated in dose-proportionality study

| Parameter | Dose of abiraterone acetate (mg/day) | Least squares meansa | Ratiosb | 90 % confidence intervalc |
|-----------|----------------------------------|---------------------|--------|--------------------------|
| Cmax (ng/mL) | 250 | 117.97 | 124.06 | 102.94–149.52 |
| | 500 | 108.77 | 114.38 | 94.96–137.78 |
| | 750 | 98.00 | 103.06 | 85.52–124.21 |
| | 1,000 | 95.09 | | |
| AUC0-last (ng h/mL) | 250 | 630.29 | 120.56 | 103.63–140.26 |
| | 500 | 586.54 | 112.19 | 96.48–130.47 |
| | 750 | 523.43 | 100.12 | 86.06–116.48 |
| | 1,000 | 522.79 | | |
| AUC0-infinity (ng h/mL) | 250 | 750.79 | 128.66 | 111.62–148.31 |
| | 500 | 663.45 | 113.69 | 98.71–130.96 |
| | 750 | 579.33 | 99.28 | 86.13–114.44 |
| | 1,000 | 583.54 | | |

Cmax = the maximum plasma concentration; AUC0-last = area under the plasma concentration–time curve (AUC) from 0 to the last measurable plasma concentration; AUC0-infinity = AUC extrapolated to infinity

PK pharmacokinetic

a Least squares (LS) means based on dose-normalized pharmacokinetic parameters from the mixed-effects model, transformed back to the linear scale (i.e., geometric means)

b Ratio of parameter means (expressed as a percent), transformed back to the linear scale. Ratios are based on dose-normalized pharmacokinetic parameters

c 90 % confidence interval for ratio of parameter means (expressed as a percent), transformed back to the linear scale. Confidence intervals are based on dose-normalized pharmacokinetic parameters
TEAEs were diarrhea, nausea, vessel puncture site pain, dizziness, and rhinorrhea, each reported by 2 (6.1%) subjects (Table 4). There were no discontinuations due to TEAEs. There were no serious adverse events (SAEs) or deaths reported during this study. No clinically significant changes were reported in hematological or clinical chemistry laboratory values, vital signs measurements, physical examinations, or 12-lead ECGs.

In the dose-escalation study, overall, 10 (31.3%) subjects [250 mg/day: 2 (7%); 500 mg/day: 5 (17%); 750 mg/day: 4 (14%); and 1,000 mg/day: 3 (10%)] experienced TEAEs. Overall, the most common TEAEs were headache, diarrhea, vessel puncture site pain, extremity pain, decreased libido, and erectile dysfunction, each reported by 2 (6.3%) subjects (Table 4). None of the TEAEs led to discontinuations during this study. No SAEs or deaths were reported. There were no reports of TEAEs related to increased mineralocorticoid levels. No clinically significant changes were observed in hematological or clinical chemistry laboratory values (except that one participant showed grade 2 abnormality: high bilirubin level on day 17, which normalized on day 21), vital signs measurements, physical examinations, or 12-lead ECGs. Administration of AA resulted in decrease in serum testosterone levels and increase in serum LH levels; however, none of these changes were clinically significant.

In the dose-escalation study, mean serum total testosterone values were generally lowest on day 3 (the first postdose timepoint at which the testosterone levels were measured in the dose-escalation study) and approached the baseline values by day 5 (Fig. 2a), and mean serum LH values were highest on day 3 and approached the baseline values by day 8 (Fig. 2b). In the dose-proportional study, oral administration of AA 250–1,000 mg/day resulted in transient decrease in the mean serum testosterone levels. The maximum decrease was observed at 12 h postdose (the first postdose timepoint at which the testosterone levels were measured in the dose-proportational study), with mean values returning to baseline by 72 h for the 250 and 500 mg doses and by 144 h for the 750 and 1,000 mg doses (Fig. 2c). Administration of AA also resulted in increase in mean serum LH levels, with maximum increase observed at 12 h postdose (Fig. 2d).

**Table 4** Treatment-emergent adverse events (TEAEs) reported by ≥2 subjects in dose-escalation study and dose-proportional study

| Dose-escalation study (N = 33) | Number of subjects with at least 1 TEAE | Diarrhea | Nausea | Site conditions | Vessel puncture site pain | Eye disorders | Nervous system disorders | Dizziness | Renal and urinary disorders | Rhinorrhea |
|-------------------------------|----------------------------------------|----------|--------|----------------|--------------------------|---------------|--------------------------|-----------|--------------------------|-----------|
|                               |                                        | 2 (6.1%) | 2 (6.1%) | 3 (9.1%) | 2 (6.1%) | 2 (6.1%) | 2 (6.1%) | 2 (6.1%) | 2 (6.1%) | 2 (6.1%) |
| Dose-proportional study (N = 32) |                                        | 10 (31.3%) | 2 (6.3%) | 2 (6.3%) | 2 (6.3%) | 2 (6.3%) | 2 (6.3%) | 2 (6.3%) | 2 (6.3%) |

**Discussion**

Abiraterone acetate appeared to be fully converted to the active moiety abiraterone, as the majority of plasma concentrations for AA were below the limit of quantification in both the studies. There was a dose-related increase in exposure of abiraterone at doses from 250 to 1,000 mg in the dose-escalation study as well as in the dose-proportional study. However, the dose-escalation study was not formally designed to assess the dose-proportionality. In the subsequent dose-proportionality study, statistical analysis of dose-normalized geometric mean showed that the decrease in abiraterone exposure from 1,000 to 750 mg was dose proportional, but the decrease at 500 and 250 mg was more than dose proportional (90% CIs outside the 80–125% range). In both studies, the mean $t_{1/2}$ and median $t_{max}$ values for abiraterone were similar across the evaluated dose range.

Total testosterone and LH levels measured in both studies indicated that the observed reduction in serum testosterone and elevation in serum LH following single dose oral administration of AA were reversible. In the dose-proportional study, the maximum effect of AA on mean serum total testosterone and LH levels occurred at the 12-h postdose, which was the first postdose timepoint at which the testosterone levels were measured in this study. Visual inspection of the concentration–time profiles for abiraterone versus total testosterone and LH levels indicated an indirect pharmacokinetic/pharmacodynamic effect as shown by the delayed pharmacodynamic response.

In both studies, AA was safe and well tolerated in fasting healthy men, over the evaluated dose range. The most common TEAEs reported by at least 2 (6.1%) subjects were diarrhea, nausea, vessel puncture site pain, dizziness, and rhinorrhea in the dose-escalation study and headache, diarrhea, vessel puncture site pain, extremity...
pain, decreased libido, and erectile dysfunction in the dose-proportionality study. There were no deaths, SAEs, or AEs, leading to discontinuation. There were no reports of adverse events of interest related to mineralocorticoid excess (e.g., fluid retention/edema, hypertension, and hypokalemia) and no adverse events of interest related to liver function test abnormalities or cardiac disorders.

Abiraterone acetate was found to be safe and well tolerated in previous phase I and II studies in patients with CRPC, when evaluated at doses of 250–1,000 mg/day; also, no dose-limiting toxicity was observed up to dose of 1,000 mg/day [12, 14–16]. The safety profile of AA observed in the present two studies was consistent with these studies and the other studies carried out in healthy men [17].

Conclusion

Abiraterone acetate (250–1,000 mg/day) appeared to be rapidly converted to abiraterone, following single dose, oral administration in healthy men. Systemic exposure to abiraterone increased with increasing doses of AA. In the dose-proportionality study, abiraterone exposure was dose proportional between 750 and 1,000 mg doses; however, the exposure was slightly greater than dose proportional when exposures at 500 and 250 mg doses were compared with the exposure at the reference dose, 1,000 mg. Abiraterone acetate was generally well tolerated in healthy men, and the safety profile was consistent with the known toxicities of AA observed in other clinical studies in patients and in healthy men.
References

1. Vishnu P, Tan WW (2010) Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 3:39–51
2. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665–1671
3. Kohli M, Tindall DJ (2010) New developments in the medical management of prostate cancer. Mayo Clin Proc 85:77–86
4. Denis L, Murphy GP (1993) Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72:3888–3895
5. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481–1488
6. Hakki T, Bernhardt R (2006) CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther 111:27–52
7. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gabler P, Torti FM, Kaplan E, Vogelzang NJ (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025–1033
8. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M (1994) Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50:267–273
9. ZYTIGA® prescribing information, updated April 2011. http://www.zytiga.com/pdf/prescribing_information.pdf. Accessed 8 Aug 2011
10. Health Canada Notice of decision for ZYTIGA , issued on 25 August 2011. http://www.hc-sc.gc.ca/dhp-msp/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/nd_ad_2011_zytiga_138343-eng.pdf. Accessed 20 Feb 2012
11. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), Assessment report for Zytiga (abiraterone), issued on 21 July 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/002321/WC500112860.pdf. Accessed 20 Feb 2012
12. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settarets S, Marriott M, Parker C, Martin V, Folkler E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563–4571
13. CTCAE N National Institutes of Health, National Cancer Institute, Common Terminology Criteria for Adverse events. Version 3.0
14. O’Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90:2317–2325
15. Attard G, Reid AH, A’Hern R, Parker C, Oommen NB, Folkert E, Messiou C, Molife LR, Maier G, Thompson E, Olimos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, De Bono JS (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742–3748
16. Reid AH, Attard G, Danila DC, Oommen NB, Olimos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, De Bono JS (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489–1495
17. Acharya M, Bernard A, Griffin T, Lopez C, Kheoh T, Tran N (2011) A phase I study to determine the effect of food on the pharmacokinetics of abiraterone acetate (AA) in healthy male subjects. Poster presented at the Annual Meeting of American Association of Pharmaceutical Scientists, Washington, DC, Oct 23–27